Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GUSB pseudogene 9 (GUSBP9) is a non-coding genomic segment derived from the GUSB gene and annotated as a pseudogene, typically due to disruptive mutations such as frameshifts or premature stop codons that render it non-functional[3][4][5]. Unlike the active GUSB gene, which encodes a lysosomal hydrolase involved in glycosaminoglycan metabolism and is relevant to inherited metabolic disorders, GUSBP9 does not produce a functional protein nor is it associated with biological or pharmacological functions. Pseudogenes, in general, may sometimes affect gene regulation at the RNA level, but no experimental data currently support such a role for GUSBP9. It is not considered a drug target, biomarker, or therapeutic entity. There is nothing to indicate active transcript, peptide, receptor, or enzyme function; the gene is likely included in annotation databases solely for completeness as a non-functional paralog in the human genome[3][4].
Not applicable (no drug interaction or target function)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucuronidase, beta pseudogene 9 (GUSBP9).